Klin Farmakol Farm. 2023;37(1):40-43 | DOI: 10.36290/far.2023.007

Subcutaneous infliximab in ankylosing spondylitis treatment

Martina Skácelová
III. interní klinika - nefrologická, revmatologická a endokrinologická, Olomouc

Infliximab, a tumor necrosis α inhibitor is newly available in subcutaneous form. This case report describes the case of a young man with ankylosing spondylitis and Crohn's disease who achieved a remission of both diseases after subcutaneous infliximab treatment.

Keywords: ankylosing spondylitis, infliximab, subcutaneous.

Accepted: April 13, 2023; Published: April 21, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Skácelová M. Subcutaneous infliximab in ankylosing spondylitis treatment. Klin Farmakol Farm. 2023;37(1):40-43. doi: 10.36290/far.2023.007.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Annals of the Rheumatic Diseases Published Online First. 2022. doi: 10.1136/ard-2022-223296. Go to original source... Go to PubMed...
    2. Urbánek K. Infliximab. Interní Med. 2017;19(1):42-46. Go to original source...
    3. www.sukl.cz.
    4. Korsten P, Strohmayer K, Baughman RP, Sweiss NJ. Refractory pulmonary sarcoidosis - proposal of a definition and recommendations for the diagnostic and therapeutic approach. Clin Pulm Med. 2016;23(2):67-75. Go to original source... Go to PubMed...
    5. Ingram JR, Woo PN, Chua SL, et al. Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality. Br J Dermatol. 2016;174(5):970-978. Go to original source... Go to PubMed...
    6. Schwartzman S. Advancements in the management of uveitis. Best Pract Res Clin Rheumatol. 2016;30(2):304-315. Go to original source... Go to PubMed...
    7. Westhovens R, Wiland P, Zawadzki M, et al. Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial. Rheumatology (Oxford). 2021;60(5):2277-2287. doi: 10.1093. Go to original source... Go to PubMed...
    8. Schreiber S, Ben-Horin S, Leszczyszyn J, et al. Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease. Gastroenterology. 2021;160(7):2340-2353. doi: 10.1053. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.